---
title: "Palmitoyl Tetrapeptide-7"
canonical_url: https://peptidelibrary.app/library/palmitoyl-tetrapeptide-7
description: "Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Palmitoyl Tetrapeptide-7

Palmitoyl Tetrapeptide-7 (also called Pal-GQPR or Rigin) is a cosmetic matrikine in the Matrix / Angiogenic class. Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling.

Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.

Also known as: Pal-GQPR, Rigin, Part of Matrixyl 3000.

Categories: Cosmetic, Experimental.

## Classification

- Type: Cosmetic matrikine
- Mechanism class: Matrix / Angiogenic
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling. Supplier and cosmetic studies describe reduced production of interleukin-6 by keratinocytes and fibroblasts after ultraviolet or inflammatory challenge. The rationale is that chronic low-grade inflammation contributes to matrix degradation in photoaged skin, so damping cytokine output is intended to slow that process rather than to stimulate collagen directly. It is most often formulated alongside palmitoyl pentapeptide-4, which acts on matrix synthesis, and most published data concerns the combination rather than the isolated ingredient.

Targets: IL-6 / dermal inflammation (cosmetic models).

Origin: Synthetic palmitoylated tetrapeptide.

## Properties

- Molecular formula: C34H62N8O7
- Molecular weight: ≈694.9 g/mol
- CAS number: 221227-05-0
- Half-life: Topical; systemic PK not established
- Studied routes: Topical

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2026

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Mondon P et al. Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using MALDI-MSI, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications. J Cosmet Dermatol. 2015. 2015. Controlled human trial. Population: People studied in vivo against placebo (number not stated in the indexed abstract). By ultrasound the blend reduced the thickness of the low-echogenic band under the epidermis and improved its density; confocal microscopy showed better dermal matrix structure than placebo [Source](https://pubmed.ncbi.nlm.nih.gov/25817264/)
2. Yang F et al. Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream. Skin Res Technol. 2024. 2024. Human study (early or uncontrolled). Population: Adults using the eye cream (number not stated in the indexed abstract). Skin hydration +28.12%, elasticity +18.81% and ultrasound collagen measure +54.99% at 12 weeks; reported as well tolerated [Source](https://pubmed.ncbi.nlm.nih.gov/38932444/)
3. Trzaska AH et al. Permeation behaviour of cosmetic actives into the human stratum corneum. Int J Pharm. 2026. 2026. Human study (early or uncontrolled). Population: 3 healthy women. Both palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 were found through every layer of the stratum corneum, between the cells rather than inside them, at falling levels with depth [Source](https://pubmed.ncbi.nlm.nih.gov/42790608/)

## Safety

Side effects: Irritation uncommon.

Risks: Cosmetic only.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Palmitoyl Tetrapeptide-7 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: OTC / Supplement

## Frequently asked questions

### What is Palmitoyl Tetrapeptide-7?

Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.

### How does Palmitoyl Tetrapeptide-7 work?

Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling. Supplier and cosmetic studies describe reduced production of interleukin-6 by keratinocytes and fibroblasts after ultraviolet or inflammatory challenge.

### Is Palmitoyl Tetrapeptide-7 FDA approved?

No. Palmitoyl Tetrapeptide-7 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Palmitoyl Tetrapeptide-7?

Reported half-life for Palmitoyl Tetrapeptide-7 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Palmitoyl Tetrapeptide-7 banned in sport?

Palmitoyl Tetrapeptide-7 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Palmitoyl Tetrapeptide-7?

Compounds most often compared with Palmitoyl Tetrapeptide-7 include Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-5, Acetyl Hexapeptide-8 and Acetyl Octapeptide-3. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [PubChem Pal-GQPR](https://pubchem.ncbi.nlm.nih.gov/compound/Palmitoyl%20tetrapeptide-7)
- [Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream — Skin Res Technol, 2024](https://pubmed.ncbi.nlm.nih.gov/38932444/)
- [Usage of Synthetic Peptides in Cosmetics for Sensitive Skin — Pharmaceuticals (Basel), 2021](https://pubmed.ncbi.nlm.nih.gov/34451799/)
- [Injectable polypeptide/chitosan hydrogel with loaded stem cells and rapid gelation promoting angiogenesis for diabetic wound healing — Int J Biol Macromol, 2025](https://pubmed.ncbi.nlm.nih.gov/40023432/)
- [Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications — J Cosmet Dermatol, 2015](https://pubmed.ncbi.nlm.nih.gov/25817264/)
